Showing 2051-2060 of 5839 results for "".
- Biosimilar News: FDA Approves Stelara Biosimilar Wezlanahttps://practicaldermatology.com/news/biosimilar-news-fda-approves-stelara-biosimilar-wezlana/2462118/The U.S. Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Stelara (ustekinumab) for psoriasis and multiple other inflammatory diseases. The FDA granted the approval of Wezlana to Amgen, Inc. Wezlana, like Stelar
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</
- Experts React to FDA Approval of Cabtreo Topical Gel for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-cabtreo-topical-gel-for-acne-vulgaris/2462087/The U.S. Food and Drug Administration (FDA) has approved CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel for the topical treatment of acne vulgaris in patients aged 12 and older. Bausch Health and Ortho Dermatologics' CABTREO is the first and
- Allergan Reports Positive Topline Results From Studies of TrenibotulinumtoxinE for Glabellar Lineshttps://practicaldermatology.com/news/allergan-reports-positive-topline-results-from-studies-of-trenibotulinumtoxine-for-glabellar-lines/2462093/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Four Grants Awarded by the GW/Pfizer Global Medical Collaborative Grant Program to Establish Teledermatology Programs in Underserved Communities Across the UShttps://practicaldermatology.com/news/four-grants-awarded-by-the-gwpfizer-global-medical-collaborative-grant-program-to-establish-teledermatology-programs-in-underserved-communities-across-the-us/2462080/The George Washington University (GW) School of Medicine and Health Sciences (SMHS), in collaboration with Pfizer Global Medical Grants, announced the four institutions that will be awarded grants to implement GW’s Teledermatology clinic model in underserved areas across the United States.&
- FDA Approves UCB’s BIMZELX for the Treatment of Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ucbs-bimzelx-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis/2462079/The U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Bimekizumab is the first and only approved psoriasis treatment desi
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- FDA Approves BMS’ Opdivo (Nivolumab) for Adjuvant Treatment of Eligible Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/fda-approves-bms-opdivo-nivolumab-for-adjuvant-treatment-of-eligible-patients-with-completely-resected-stage-iib-or-iic-melanoma/2462074/The U.S. Food and Drug Administration (FDA) has given its nod to Opdivo (nivolumab) for the adjuvant treatment of eligible adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma. This approval was based on the Phase 3